|
|
|
|
|
Legal status
Patent expired
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| C12N 15/13 | (2006.01) | ||
| C12N 15/85 | (2006.01) | ||
| C12N 5/10 | (2006.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61K 31/7088 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 1504035 |
| (13) | Kind of document | T |
| (96) | European patent application number | 03718974.3 |
| Date of filing the European patent application | 2003-05-02 | |
| (97) | Date of publication of the European application | 2005-02-09 |
| (45) | Date of publication and mention of the grant of the patent | 2010-03-31 |
| (46) | Date of publication of the claims translation | 2010-08-25 |
| (86) | Number | PCT/GB2003/001934 |
| Date | 2003-05-02 |
| (87) | Number | WO 2003/093320 |
| Date | 2003-11-13 |
| (30) | Number | Date | Country code |
| 0210121 | 2002-05-02 | GB |
| (72) |
POPPLEWELL, Andrew George, GB
TICKLE, Simon Peter, GB
LADYMAN, Heather Margaret, GB
|
| (73) |
UCB Pharma, S.A.,
Allée de La Recherche 60, 1070 Brussels,
BE
|
| (74) |
Marius JAKULIS - JASON,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas |
| ANTIBODIES SPECIFIC FOR HUMAN CD22 AND THEIR THERAPEUTIC AND DIAGNOSTIC USES |
| Payment date | Validity (years) | Amount | |
| 2022-04-28 | 347.00 EUR |